Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya

Christine J. McGrath, Julia Njoroge, Grace C. John-Stewart, Pamela K. Kohler, Sarah F. Benki-Nugent, Joan W. Thiga, Anthony Etyang, Michael H. Chung

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4Tbased and 269 (15%) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.

Original languageEnglish (US)
Pages (from-to)200-204
Number of pages5
JournalJournal of neurovirology
Volume18
Issue number3
DOIs
StatePublished - Jun 1 2012

    Fingerprint

Keywords

  • Africa
  • Antiretroviral therapy
  • HIV
  • Peripheral neuropathy
  • Toxicity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this

McGrath, C. J., Njoroge, J., John-Stewart, G. C., Kohler, P. K., Benki-Nugent, S. F., Thiga, J. W., Etyang, A., & Chung, M. H. (2012). Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya. Journal of neurovirology, 18(3), 200-204. https://doi.org/10.1007/s13365-012-0098-x